Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$49.96
-$0.51(-1.26%)
At close: 4:00 PM EST
$49.96
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$27.07 - $56.54
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.28M
Market Cap
$6.59B
Enterprise Value$5.40B
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 12, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume1,257,976
30 Day Avg. Volume1,279,554
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-105.41
Enterprise Value/Ebitda-13.51
Forecast
1Y Price Target
$59.63Price Target Upside19.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress And Dual Supply PathFDA acceptance with a clear PDUFA date and inclusion of two independent fill-finish sites materially improves the company's pathway to commercialization. This durable regulatory progress shortens time-to-revenue potential and reduces single-site supply risk if approval is granted.
Material Cash Balance And Financing OptionalityA substantial cash position combined with ATM proceeds, a recent $100M debt draw and an approval-triggered $150M option provides runway and financing flexibility. This durable liquidity and optionality reduce near-term refinancing risk and support prelaunch investments through commercialization.
Commercial Launch Infrastructure In PlaceEstablished provider relationships, specialty pharmacy access and home‑infusion channels create durable go-to-market capabilities. This infrastructure accelerates patient access and uptake post-approval, lowering commercialization execution risk versus building these networks from scratch.
Bears Say
Large, Persistent Cash BurnSustained negative operating and free cash flow at scale indicates the company relies on external funding to sustain operations. Over months this increases dilution and strategic dependency on financing outcomes, pressuring long-term durability if commercial timing slips or revenue ramps more slowly than expected.
Rising Debt And Higher LeverageDebt growth and rising debt-to-equity indicate increasing fixed obligations and reduced financial flexibility. In a pre-revenue biotech, higher leverage amplifies refinancing and covenant risk, constraining investment optionality and increasing reliance on successful clinical and regulatory milestones to avoid distress.
Manufacturing Approvability Uncertainty (Catalent)Regulatory classification of a critical fill-finish site remains unresolved. This structural regulatory/manufacturing uncertainty can delay approval, constrain initial supply and complicate EMA timing, creating sustained execution risk that directly affects commercial launch readiness and revenue realization.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $56.54 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $6.59B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.63 (19.35% Upside)
$59.63 (19.35% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.47%
12-Months-Change
Fundamentals
Return on Equity
-163.52%
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Company Deck
SRRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$59.63
▲(19.35% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.61% Insiders
28.70% Mutual Funds
15.99% Other Institutional Investors
24.78% Public Companies and
Individual Investors